Company Overview and News

0
IMED / ETF Managers Trust null

2018-07-18 sec.gov
ETF Managers Trust
IMED

0
IMED / ETF Managers Trust SUPPLEMENTARY MATERIALS FOR XBRL

2018-07-09 sec.gov
Filed Pursuant to Rule 497(e)
IMED

0
IMED / ETF Managers Trust SUPPLEMENTARY MATERIALS

2018-06-29 sec.gov
Filed pursuant t
IMED

0
IMED / ETF Managers Trust 485BXT

2018-06-28 sec.gov
As filed with the U.S. Securities and Exchange Commission on June 28, 2018 File No.: 333-182274 File No.: 811-22310
IMED

0
IMED / ETF Managers Trust POST EFFECTIVE AMENDMENT - RULE 485B FOR XBRL

2018-06-21 sec.gov
As filed with the U.S. Securities and Exchange Commission on June 21, 2018
IMED

0
IMED / ETF Managers Trust NYSE ARCA CERTIFICATION

2018-06-20 sec.gov
begin 644 BIKR.8A.06.20.18.pdf M)5!$1BTQ+C4*):;IS\0-"[email protected],"!O8FH*/#P*+TQE;F=T:" U(# @[email protected] M=&5R("]&;&%T941E8V]D90H^/@IS=')E86T-"GC:E5?;;ALW$'W75^PC"43, M\K(DMV^)([<.D "M!1A!T0=55BRWNCB6G,[email protected]+N<'"N\[J.23DI&]J(+8$37-YT33C4]_D5_;Z>C MUY>R\:+5S?3S2 :+LLG;-,!HINO1G^PM'UOAV8*/.R'9YI\9EYVP;,W''L3W M'!]N^%BI3K3L&K44"SJ.?0,Q['GFLH4=P4++'OE?T_>CR;2"J:7PKO%62'L* M4[T(4QO1&H+Y&Q^;X,0 GMDM @+J;,NUZ-EG6$H'-Q>$ :4>D'1"LP>[email protected]$ M;"B9[3F$%O$J\*/8&SY&]3FH&+9'[email protected]^[email protected]=B6O'^"68,D3[H]@PD38 M&"]E ?4GC+F,YA&48O\2!8TA-G#9\X,&(K-)P[ ))>$[BB5;!G0S!.
IMED

0
IMED / ETF Managers Trust DEFINITIVE MATERIALS

2018-06-13 sec.gov
Rogers AI Global Macro ETF
IMED

0
IMED / ETF Managers Trust REGISTRATION OF CERTAIN CLASSES OF SECURITIES

2018-06-11 sec.gov
As filed with the Securities and Exchange Commission on June 11, 2018
IMED

0
IMED / ETF Managers Trust POST EFFECTIVE AMENDMENT - RULE 485B

2018-06-08 sec.gov
As filed with the U.S. Securities and Exchange Commission on June 8, 2018
IMED

0
IMED / ETF Managers Trust DESIGNATION OF NEW EFFECTIVE DATE

2018-06-05 sec.gov
As filed with the U.S. Securities and Exchange Commission on June 5, 2018
IMED

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to IMED / ETF Managers Trust on message board site Silicon Investor.

Amazon Fire u0026 Kindle Fire Multimedia Tablets ... TMMI - Total Multimedia
Multimedia Games Inc. (MGAM) Valimed
CDEX/Valimed Longs (Bulls Board) Real(?)/ claimed MPG
Primedia / About.com Primedex Health Systems, Inc. (Nasdaq BB: PMDX)
TMED Trimedine Inc. Omni Multimedia Group OMG-AMEX